355 related articles for article (PubMed ID: 27021928)
1. Cetuximab treatment alters the content of extracellular vesicles released from tumor cells.
van Dommelen SM; van der Meel R; van Solinge WW; Coimbra M; Vader P; Schiffelers RM
Nanomedicine (Lond); 2016 Apr; 11(8):881-90. PubMed ID: 27021928
[TBL] [Abstract][Full Text] [Related]
2. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.
Montermini L; Meehan B; Garnier D; Lee WJ; Lee TH; Guha A; Al-Nedawi K; Rak J
J Biol Chem; 2015 Oct; 290(40):24534-46. PubMed ID: 26272609
[TBL] [Abstract][Full Text] [Related]
4. PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells.
Fang Y; Garnier D; Lee TH; D'Asti E; Montermini L; Meehan B; Rak J
Angiogenesis; 2016 Jan; 19(1):25-38. PubMed ID: 26374632
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicles as biomarkers and therapeutic targets for cancer.
Urabe F; Kosaka N; Ito K; Kimura T; Egawa S; Ochiya T
Am J Physiol Cell Physiol; 2020 Jan; 318(1):C29-C39. PubMed ID: 31693397
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles.
Samuel P; Fabbri M; Carter DRF
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28941129
[TBL] [Abstract][Full Text] [Related]
7. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Calderwood SK; Okamoto K; Kozaki KI
Oral Oncol; 2018 Nov; 86():251-257. PubMed ID: 30409309
[TBL] [Abstract][Full Text] [Related]
8. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation.
Choi D; Lee TH; Spinelli C; Chennakrishnaiah S; D'Asti E; Rak J
Semin Cell Dev Biol; 2017 Jul; 67():11-22. PubMed ID: 28077296
[TBL] [Abstract][Full Text] [Related]
10. Emerging techniques in the isolation and characterization of extracellular vesicles and their roles in cancer diagnostics and prognostics.
Sunkara V; Woo HK; Cho YK
Analyst; 2016 Jan; 141(2):371-81. PubMed ID: 26535415
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
[TBL] [Abstract][Full Text] [Related]
12. Cancer cell line-specific protein profiles in extracellular vesicles identified by proteomics.
Guerreiro EM; Øvstebø R; Thiede B; Costea DE; Søland TM; Kanli Galtung H
PLoS One; 2020; 15(9):e0238591. PubMed ID: 32886718
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
14. Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms.
Gomes FG; Sandim V; Almeida VH; Rondon AMR; Succar BB; Hottz ED; Leal AC; Verçoza BRF; Rodrigues JCF; Bozza PT; Zingali RB; Monteiro RQ
Thromb Res; 2017 Nov; 159():24-32. PubMed ID: 28950217
[TBL] [Abstract][Full Text] [Related]
15. Extracellular Vesicles and Their Role in Urologic Malignancies.
Junker K; Heinzelmann J; Beckham C; Ochiya T; Jenster G
Eur Urol; 2016 Aug; 70(2):323-31. PubMed ID: 26924769
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
17. Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells.
Dhupkar P; Dowling M; Cengel K; Chen B
Anticancer Res; 2010 Jun; 30(6):1905-10. PubMed ID: 20651333
[TBL] [Abstract][Full Text] [Related]
18. A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix.
Liang H; Li X; Wang B; Chen B; Zhao Y; Sun J; Zhuang Y; Shi J; Shen H; Zhang Z; Dai J
Sci Rep; 2016 Feb; 6():18205. PubMed ID: 26883295
[TBL] [Abstract][Full Text] [Related]
19. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Use of Tumor Cell-Derived Extracellular Vesicles.
Liu J; Ma J; Tang K; Huang B
Methods Mol Biol; 2017; 1660():433-440. PubMed ID: 28828677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
